UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of
1934
Date of
Report (Date of Earliest Event Reported): August 18,
2017
MetaStat, Inc.
(Exact
name of registrant as specified in its charter)
Nevada
(State
or other jurisdiction of incorporation)
|
000-52735
|
20-8753132
|
|
(Commission File
Number)
|
(IRS Employer
Identification No.)
|
27 Drydock Avenue, 2nd Floor
Boston, MA 02210
(Address
of principal executive offices and zip code)
(617) 531-6500
(Registrant's
telephone number including area code)
(Registrant's
former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of registrant under
any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[
] Soliciting material pursuant to Rule 14a-12(b) under the Exchange
Act (17 CFR 240.14a-12(b))
[
] Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Entry into a Material Definitive
Agreement.
On
August 18, 2017, MetaStat, Inc. (“MetaStat”) received
payment of $146,022 from Celgene Corporation (“Celgene”) for
satisfactory completion of the third of four milestones pursuant to
the pilot materials transfer agreement, as amended (the
“Research
Agreement”) between the parties.
MetaStat
has successfully completed testing of Celgene’s proprietary
materials in its nonclinical cell line models and is currently
testing in its nonclinical animal models. Additionally, the term of
the Research Agreement was extended by the parties through December
22, 2017. To date, MetaStat has received an aggregate of $876,134
from Celgene pursuant to the Research Agreement.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
|
Dated: August 22,
2017
|
METASTAT,
INC.
By:
/s/ Douglas A.
Hamilton
Name: Douglas A. Hamilton
Title: President and CEO
|